Skip to content

Identification of biomarkers, functional parameters and clinical risk factors predisposing for the development of pulmonary chronic GVHD after allogeneic hematopoietic stem cell transplantation.

Identification of biomarkers, functional parameters and clinical risk factors predisposing for the development of pulmonary chronic GVHD after allogeneic hematopoietic stem cell transplantation.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00003304
Enrollment
250
Registered
2011-11-02
Start date
2011-12-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obliterative bronchiolitis, bronchiolitis obliterans with organizing pneumonia (BOOP), non-classifiable interstitial pneumonia (NCIP) chronic GVHD, ICD-10: T86.05, T86.06, T86.07 T86.06 T86.06

Interventions

Group 1: Hematopoietic stem cell recipients with chronic GVHD. Regular measurement of serological, cytogenetic, molecular and cellular markers in the blood. Pulmonary function tests, radiological test

Sponsors

Westdeutsches Tumorzentrum Klinik für Knochenmarktransplantation Universitätsklinikum Essen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: free of relapse after allogeneic HSCT

Exclusion criteria

Exclusion criteria: relapse

Design outcomes

Primary

MeasureTime frame
Incidence rates of obliterative bronchiolitis (BO), bronchiolitis obliterans with organizing pneumonia (BOOP), non-classifiable interstitial pneumonia (NCIP). Correlation with clinical risk factors and Biomarkers (TIM-1a, Elafin, BAF, NFkappaB, TGFbeta, HIF1a, Il-17, FoxP3, INOS, IDO, TLR-2, TLR-9, Wnt/beta-catenin, sIl-2, T-regs)

Secondary

MeasureTime frame
Incidence rates of chronic GVHD. Correlation with clinical risk factors and Biomarkers (TIM-1a, Elafin, BAF, NFkappaB, TGFbeta, HIF1a, Il-17, FoxP3, INOS, IDO, TLR-2, TLR-9, Wnt/beta-catenin, sIl-2, T-regs)

Countries

Germany

Contacts

Public ContactMarkus Ditschkowski

Westdeutsches Tumorzentrum Klinik für Knochenmarktransplantation Universitätsklinikum Essen

markus.ditschkowski@uk-essen.de0201-723-3136

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026